There are some new approaches to hypertension coming out. The first is a new class of medication:

There are a few new agents in the pipeline that hold promise. One novel class of medications, called oral Renin inhibitors, works by targeting an Enzyme released by the kidneys that can affect blood pressure. The first of these agents to be introduced on the market is likely to be Aliskiren, a Novartis drug currently in phase III testing. Analysts expect the company to seek regulatory approval in 2006 and are forecasting blockbuster sales topping $1 billion by 2008 and reaching $3.6 billion by 2012, LeadDiscovery reports.

The other is an implantable device:

Meantime, even a gadget to keep blood pressure at bay is being tested. In March, doctors at the University of Rochester Medical were the first in the nation to implant the Rheos, a battery-operated generator that activates the body's natural blood pressure regulation systems. Much like a pacemaker regulates heart rhythm, this device stimulates nerves in the carotid arteries to tell the brain to reduce blood pressure. Bisognano is part of the team that is testing the device.

Despite these approaches, prevention is key:

Still, preventing hypertension in the first place is a far better thing than having to rely on medicines or machines, clinicians agree. That is why the National Hypertension Association (NHA) has focused on basic research and education.

(Pallarito, "New Hope for Those With High Blood Pressure", Forbes, Jul23; MedGadget, "Novel Device for High Blood Pressure Implanted", Apr.1)